KARD

11.8305.51%
DP

David P. Meeker

Independent Director

Dr. David P. Meeker, MD, is Member of Advisory Board of Mitotherapeutix, LLC. Dr. Meeker had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meeker has been a Director of Rhythm Pharmaceuticals, Inc. since November 2015 and serves as its Chairman of the Board since April 2017. Dr. Meeker serves as a Director at Kardigan, Inc since October 2024. Dr. Meeker serves as Chief Executive Officer and President at Rhythm Pharmaceuticals, Inc. since July 20, 2020. Dr. Meeker served as President and Chief Executive Officer of KSQ Therapeutics, Inc. from September 2017 to July 2020. Dr. Meeker served as an Executive Vice President and General Manager of Genzyme at Sanofi US Services Inc. since November 2011 until July 6, 2017. Dr. Meeker served as the Chief Executive Officer and President of Genzyme Corporation from October 25, 2011 until June 30, 2017. Dr. Meeker had overseen and provided the vision for two business units – Rare Diseases and Multiple Sclerosis. Dr. Meeker served as Chief Executive Officer of Genzyme Polyclonals S.A.S. since November 2011 and its Chief Operating Officer since 2009. He served as an Executive Vice President of Specialty Care and Head of Sanofi Genzyme since November 2011 until February 17, 2016. Dr. Meeker oversaw the company’s specialty business units-Rare Diseases, Multiple Sclerosis, Oncology and Immunology. He has also served as chairman of the board of directors of Trevi Pharmaceuticals, Inc. (Nasdaq: TRVI) since July 2017. He served as the Chief Operating Officer at Genzyme Corporation from March 2009 to March 2010 and served as its Executive Vice President. He was responsible for Genzyme’s commercial organization, overseeing its business units¸ country management organization and global market access functions. He served as Executive Vice President of Genetic Diseases Biosurgery & Corporate Operations at Genzyme Corporation from March 2009 to March 2010 and also served as its Executive Vice President of Therapeutics, Genetic Diseases Biosurgery & Transplant since May 2008 and its Chief Executive Officer and President since July 2020. He served as the President of LSD (Lysosomal Storage Disorders Therapeutics), Business Unit of Genzyme Corporation since 2003. He served as Corporate Vice President of Genzyme Molecular Oncology Inc. He served as the President of Lysosomal Storage Disorders Business Unit at Genzyme Oncology, Inc. Dr. Meeker has served in various roles at Genzyme Corporation since 1994, including Senior Vice President of Therapeutics Europe from May 2000 to March 2003 and Senior Vice President of Medical Affairs from June 1998 to May 2000. He joined Genzyme Corporation in 1994 as Medical Director and worked on the Cystic Fibrosis Gene Therapy Program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to joining Genzyme in 1994, he served as a Director of the Pulmonary Critical Care Fellowship of the Cleveland Clinical Foundation. He has been Independent Chairman of the Board at Trevi Therapeutics, Inc. since July 20, 2017. Dr. Meeker has been the Chairman of the Board of Rhythm Holding Company, LLC since November 2015 and as its Director since December 2015. He has been the Chairman of Allergan GI Corp. since April 2017 and previously served the same position December 16, 2015. He served as a Director of Savient Pharmaceuticals, Inc. since January 7, 2013. He has been Director of Turmeric Acquisition Corp. He served as a Director of Penwest Pharmaceuticals Co. from January 4, 2007 to September 20, 2010. He is a Board Member of the Biotechnology Industry Organization and of Prize4Life. He served an Assistant Professor of Medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters. He served as an Independent Director of MyoKardia, Inc. since April 18, 2017 until November 16, 2020 (acquisition done by Bristol Myers Squibb). He has deep experience as a senior executive at global pharmaceutical companies and was involved in the development and commercialization of pharmaceutical product candidates for the treatment of rare and ultra-rare diseases. He completed Clinical Fellowship in Medicine from Harvard Medical School, post- doctoral training in Pulmonary Medicine from Boston University and Fellowship in Pulmonary Medicine from Boston University, an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. He earned an M.D. from the University of Vermont Medical School. Dr. Meeker completed the Advanced Management Program at Harvard Business School in 2000.

Positions